EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Transcriptome‐Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy of Overall Survival Following Adjuvant Treatment

Marjolein F Lansbergen iD, Vincent R Lanting, Paul Manoukian, Marc G Besselink, Geert Kazemier, Ignace H J T de Hingh, Mike S L Liem, Casper H J van Eijck, Erwin van der Harst, Vincent E de Meijer, Ronald M van Dam, Martijn W J Stommel und 9 weitere

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70519 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Marjolein F Lansbergen und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Transcriptome. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ZonMw.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In pancreatic ductal adenocarcinoma, patient outcomes after resection remain highly variable. Prognostic models are often inaccurate. Our study aimed to improve survival prediction by adding transcriptome‐based classification to a validated prognostic model and applying it on a multicenter real‐world cohort of fresh‐frozen resection materials. RNA was sequenced if tumor cellularity was > 30%. The samples were classified using transcriptome‐based classification. Survival differences between transcriptome‐based subtypes were studied in patients treated with and without adjuvant chemotherapy. 25.6% of the patients received neoadjuvant treatment (NAT). Samples of 461 patients were collected, of which 118 samples underwent RNA sequencing. Of those, 39.0% had a basal‐like subtype and 61.0% had a classical subtype. The basal‐like subtype became dominant after NAT (63.3%, p = 0.004). Patients with a classical tumor survived longer than those with a basal‐like tumor (median overall survival [OS]: 22.8 vs. 11.4 months; p < 0.001, in patients receiving adjuvant gemcitabine, and 10.7 vs. 5.4 months; p = 0.082, in patients without adjuvant treatment). In multivariable Cox regression, the classical subtype significantly associated with increased survival (hazard ratio = 0.38; p = 0.002) and adding transcriptome‐based subtyping significantly improved the prognostic model ( p = 0.002). Subtype and adjuvant treatment independently significantly associated with OS. Transcriptome‐based subtyping significantly adds to clinical variables in survival prediction after surgery. The independent associations for subtype and adjuvant treatment with OS indicate that subtypes are prognostic, but not predictive for OS with adjuvant treatment. The provided prognostic information could potentially support treatment decisions and serve as stratification factor.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsTranscriptomeAgedFemaleHumansMaleMiddle AgedChemotherapy, AdjuvantDeoxycytidineGemcitabineGene Expression ProfilingNeoadjuvant TherapyPrognosis

Stichwörter der Autor:innen

RNA sequencingadjuvant chemotherapypancreatic cancerresectionsubtypes

Substanzen

DeoxycytidineGemcitabine

Autor:innen und Institutionen

  • Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
  • Laboratory of Experimental Oncology and Radiobiology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
  • Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands.
  • Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
  • Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands.
  • Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

ORCID-Profile: Marjolein F Lansbergen, Maarten F Bijlsma

Förderung

  • ZonMw

Zitieren

APA

Lansbergen, M. F., Lanting, V. R., Manoukian, P., Besselink, M. G., Kazemier, G., de Hingh, I. H. J. T., Liem, M. S. L., van Eijck, C. H. J., van der Harst, E., de Meijer, V. E., van Dam, R. M., Stommel, M. W. J., Koster, J., Tanck, M. W. T., Fariña Sarasqueta, A., Verheij, J., Dijk, F., Wilmink, J. W., Bijlsma, M. F., …, & Dutch Pancreatic Cancer Group (2026). Transcriptome‐Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy of Overall Survival Following Adjuvant Treatment. International Journal of Cancer. https://doi.org/10.1002/ijc.70519

Vancouver

Lansbergen MF, Lanting VR, Manoukian P, Besselink MG, Kazemier G, de Hingh IHJT, et al. Transcriptome‐Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy of Overall Survival Following Adjuvant Treatment. International Journal of Cancer. 2026. doi:10.1002/ijc.70519

BibTeX
@article{Lansbergen2026,
  author = {Lansbergen, Marjolein F and Lanting, Vincent R and Manoukian, Paul and Besselink, Marc G and Kazemier, Geert and de Hingh, Ignace H J T and Liem, Mike S L and van Eijck, Casper H J and van der Harst, Erwin and de Meijer, Vincent E and van Dam, Ronald M and Stommel, Martijn W J and Koster, Jan and Tanck, Michael W T and Fariña Sarasqueta, Arantza and Verheij, Joanne and Dijk, Frederike and Wilmink, Johanna W and Bijlsma, Maarten F and van Laarhoven, Hanneke W M and Dutch Pancreatic Cancer Group, Dutch Pancreatic Cancer Group},
  title = {Transcriptome‐Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy of Overall Survival Following Adjuvant Treatment},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70519}
}
Kostenlos starten →